Each film-coated tablet contains 50 mg and 100 mg.
Losartan potassium (KENZAR) is an angiotensin II receptor antagonist with antihypertension activity.
Pharmacology: Pharmacokinetics: Losartan potassium (KENZAR) is readily absorbed from the gastrointestinal tract following oral administration. It undergoes first pass metabolism to form an active carboxylic acid metabolite which has a greater pharmacological activities. Peak plasma concentration is achieved in about 1 hour after an oral dose. It is 98% bound to plasma protein. It is excreted in urine and in feces as unchanged drug and metabolites. Following oral dose, about 4% of the dose is excreted unchanged in urine and about 6% in urine as the active metabolite.
It is used in the management of hypertension, particularly in the patients who develop cough with Angiotensin Converting Enzyme (ACE) Inhibitors and to reduce the risk of stroke in patients with left ventricular hypertrophy and in the treatment of diabetic nephropathy.
In hypertension, the usual starting and maintenance dose is 50 mg once daily. The dose may be increased if necessary to 100 mg daily based on blood pressure response in one or two divided doses.
For patients with intravascular volume-depletion (e.g., those treated with high-dose diuretics) a starting dose of 25 daily should be considered.
An initial dose of 25 mg once daily is suggested for the elderly over 75 years of age.
Losartan potassium (KENZAR) may be administered with or without food.
In diabetic nephropathy, an initial dose of 50 mg once daily. increased to 100 mg once daily depending on blood pressure.
Losartan potassium is contraindicated in patients who are hypersensitive to any component of this product.
Should not be given during pregnancy and lactation, contraindicated to patients with renal artery stenosis and hyperkalemia. It should not be used along with potassium-sparing diuretics.
Should not be given during pregnancy and lactation.
Adverse effects have been reported to be usually mild and transient in nature. The most common drug-related side effects were dizziness, asthenia/fatigue and vertigo. The overall incidence of side effects reported with Losartan potassium was comparable to placebo.
In clinical pharmacokinetic trials, no drug interactions of clinical significance have been identified with hydrochlorothiazide, digoxin, warfarin, cimetidine, phenobarbital, ketoconazole, and erythromycin. Rifampin and fluconazole have been reported to reduce levels of active metabolite. The clinical consequences of these interactions have not been evaluated.
As with other drugs that block angiotensin II or its effects.
Concomitant use of potassium-sparing diuretics (e.g. spironolactone, triamterene, amiloride) potassium supplements or salt-containing potassium may lead to increases in serum potassium.
As with other antihypertensive agents, the antihypertensive effect of losartan may be attenuated by the non-steroidal anti-inflammatory drug indomethacin.
Store at temperatures not exceeding 30°C. Protect from light.
C09CA01 - losartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.
FC tab 50 mg x 30's. 100 mg x 30's.